Cargando…
An integrated risk predictor for pulmonary nodules
It is estimated that over 1.5 million lung nodules are detected annually in the United States. Most of these are benign but frequently undergo invasive and costly procedures to rule out malignancy. A risk predictor that can accurately differentiate benign and malignant lung nodules could be used to...
Autores principales: | Kearney, Paul, Hunsucker, Stephen W., Li, Xiao-Jun, Porter, Alex, Springmeyer, Steven, Mazzone, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435179/ https://www.ncbi.nlm.nih.gov/pubmed/28545097 http://dx.doi.org/10.1371/journal.pone.0177635 |
Ejemplares similares
-
Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules
por: Vachani, Anil, et al.
Publicado: (2015) -
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
por: Silvestri, Gerard A., et al.
Publicado: (2018) -
Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules
por: Vachani, Anil, et al.
Publicado: (2015) -
Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic
por: Springmeyer, Steven C., et al.
Publicado: (2020) -
Assessing a biomarker’s ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study
por: Pritchett, Michael A., et al.
Publicado: (2023)